News
News & publications
News & publications
September 4, 2024
Press Release
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
Featured
November 14, 2024
Podcast
Samir Ounzain: Unlocking the Power of the Dark Genome
November 14, 2024
Podcast
Samir Ounzain: Unlocking the Power of the Dark Genome
November 12, 2024
Podcast
Targeting the Dark Matter of the Genome to Treat Diseases
November 12, 2024
Podcast
Targeting the Dark Matter of the Genome to Treat Diseases
November 4, 2024
News
Reprogramming the software of the cell to fight disease
November 4, 2024
News
Reprogramming the software of the cell to fight disease
September 11, 2024
Press Release
HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer
September 11, 2024
Press Release
HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer
July 18, 2024
Press Release
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
July 18, 2024
Press Release
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
July 1, 2024
Press Release
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award
July 1, 2024
Press Release
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award
September 6, 2023
News
HAYA Therapeutics wins the top prize at the TOP 100 Swiss Startup Award 2023
September 6, 2023
News
HAYA Therapeutics wins the top prize at the TOP 100 Swiss Startup Award 2023
July 17, 2023
News
Junk DNA: how the dark genome is changing RNA therapies
July 17, 2023
News
Junk DNA: how the dark genome is changing RNA therapies
June 20, 2023
Press Release
HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board
June 20, 2023
Press Release
HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board
May 17, 2023
Podcast
RNA-guided programmable therapeutics for fibrosis
May 17, 2023
Podcast
RNA-guided programmable therapeutics for fibrosis
April 14, 2023
Podcast
The dark genome as the next revolution in drug discovery
April 14, 2023
Podcast
The dark genome as the next revolution in drug discovery
April 12, 2023
News
The mystery of the human genome's dark matter
April 12, 2023
News
The mystery of the human genome's dark matter
February 16, 2023
Press Release
HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards
February 16, 2023
Press Release
HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards
January 23, 2023
News
RNA companies to watch over the next 12 months
January 23, 2023
News
RNA companies to watch over the next 12 months
January 11, 2023
Blog Post
Why fibrosis matters in cardiovascular diseases: the role of the dark genome
January 11, 2023
Blog Post
Why fibrosis matters in cardiovascular diseases: the role of the dark genome
December 5, 2022
News
Drug discovery startups set to take-off
December 5, 2022
News
Drug discovery startups set to take-off
October 25, 2022
News
Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report
October 25, 2022
News
Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report
September 29, 2022
News
18 European techbio startups to watch — according to investors
September 29, 2022
News
18 European techbio startups to watch — according to investors
September 27, 2022
News
HAYA Therapeutics: sur la piste de la fibrose
September 27, 2022
News
HAYA Therapeutics: sur la piste de la fibrose
September 15, 2022
Press Release
HAYA Therapeutics Appoints Brian C. Thomas, Ph.D., as Chairperson of the Board of Directors
September 15, 2022
Press Release
HAYA Therapeutics Appoints Brian C. Thomas, Ph.D., as Chairperson of the Board of Directors
May 4, 2022
News
What dark matter means for the future of therapeutics
May 4, 2022
News
What dark matter means for the future of therapeutics
May 3, 2022
Press Release
HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies
May 3, 2022
Press Release
HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies
April 25, 2022
Podcast
Building Biotech Series with Samir Ounzain
April 25, 2022
Podcast
Building Biotech Series with Samir Ounzain
April 11, 2022
News
7 Top BioPharma Startups & Companies (Vaud)
April 11, 2022
News
7 Top BioPharma Startups & Companies (Vaud)
February 15, 2022
Blog Post
HAYA’s Journey: From Dinosaurs to Torrey Pines
February 15, 2022
Blog Post
HAYA’s Journey: From Dinosaurs to Torrey Pines
February 9, 2022
Press Release
HAYA Therapeutics Establishes U.S. Location
February 9, 2022
Press Release
HAYA Therapeutics Establishes U.S. Location
October 28, 2021
News
Delivery & Safety Top Concerns as BIO-Europe Plumbs Future of Gene Therapy
October 28, 2021
News
Delivery & Safety Top Concerns as BIO-Europe Plumbs Future of Gene Therapy
August 11, 2021
Podcast
Unleashing The Power of a Non-Coding Genome With Dr. Samir Ounzain
August 11, 2021
Podcast
Unleashing The Power of a Non-Coding Genome With Dr. Samir Ounzain
August 10, 2021
Press Release
HAYA Therapeutics Announces Scientific Advisory Board
August 10, 2021
Press Release
HAYA Therapeutics Announces Scientific Advisory Board
May 20, 2021
Press Release
HAYA Therapeutics Completes CHF 18 Million Seed Financing to Advance Anti-fibrotic Therapies Targeting Long Non-Coding RNAs
May 20, 2021
Press Release
HAYA Therapeutics Completes CHF 18 Million Seed Financing to Advance Anti-fibrotic Therapies Targeting Long Non-Coding RNAs
May 20, 2021
News
HAYA, RenBio Launch with Sights Set on Clinic
May 20, 2021
News
HAYA, RenBio Launch with Sights Set on Clinic
May 20, 2021
News
HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs
May 20, 2021
News
HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs
September 11, 2024
Press Release
HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer
September 11, 2024
|
Press Release
HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer
September 4, 2024
Press Release
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
September 4, 2024
|
Press Release
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
July 18, 2024
Press Release
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
July 18, 2024
|
Press Release
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
July 1, 2024
Press Release
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award
July 1, 2024
|
Press Release
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award
June 20, 2023
Press Release
HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board
June 20, 2023
|
Press Release
HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board
February 16, 2023
Press Release
HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards
February 16, 2023
|
Press Release
HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards
September 15, 2022
Press Release
HAYA Therapeutics Appoints Brian C. Thomas, Ph.D., as Chairperson of the Board of Directors
September 15, 2022
|
Press Release
HAYA Therapeutics Appoints Brian C. Thomas, Ph.D., as Chairperson of the Board of Directors
May 3, 2022
Press Release
HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies
May 3, 2022
|
Press Release
HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies
February 9, 2022
Press Release
HAYA Therapeutics Establishes U.S. Location
February 9, 2022
|
Press Release
HAYA Therapeutics Establishes U.S. Location
November 4, 2024
|
News
Reprogramming the software of the cell to fight disease
November 4, 2024
News
Reprogramming the software of the cell to fight disease
September 6, 2023
|
News
HAYA Therapeutics wins the top prize at the TOP 100 Swiss Startup Award 2023
September 6, 2023
News
HAYA Therapeutics wins the top prize at the TOP 100 Swiss Startup Award 2023
July 17, 2023
|
News
Junk DNA: how the dark genome is changing RNA therapies
July 17, 2023
News
Junk DNA: how the dark genome is changing RNA therapies
April 12, 2023
|
News
The mystery of the human genome's dark matter
April 12, 2023
News
The mystery of the human genome's dark matter
January 23, 2023
|
News
RNA companies to watch over the next 12 months
January 23, 2023
News
RNA companies to watch over the next 12 months
December 5, 2022
|
News
Drug discovery startups set to take-off
December 5, 2022
News
Drug discovery startups set to take-off
October 25, 2022
|
News
Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report
October 25, 2022
News
Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report
September 29, 2022
|
News
18 European techbio startups to watch — according to investors
September 29, 2022
News
18 European techbio startups to watch — according to investors
September 27, 2022
|
News
HAYA Therapeutics: sur la piste de la fibrose
September 27, 2022
News
HAYA Therapeutics: sur la piste de la fibrose
May 4, 2022
|
News
What dark matter means for the future of therapeutics
May 4, 2022
News
What dark matter means for the future of therapeutics
April 11, 2022
|
News
7 Top BioPharma Startups & Companies (Vaud)
April 11, 2022
News
7 Top BioPharma Startups & Companies (Vaud)
October 28, 2021
|
News
Delivery & Safety Top Concerns as BIO-Europe Plumbs Future of Gene Therapy
October 28, 2021
News
Delivery & Safety Top Concerns as BIO-Europe Plumbs Future of Gene Therapy
May 20, 2021
|
News
HAYA, RenBio Launch with Sights Set on Clinic
May 20, 2021
News
HAYA, RenBio Launch with Sights Set on Clinic
May 20, 2021
|
News
HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs
May 20, 2021
News
HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs
November 14, 2024
|
Podcast
Samir Ounzain: Unlocking the Power of the Dark Genome
November 14, 2024
Podcast
Samir Ounzain: Unlocking the Power of the Dark Genome
November 12, 2024
|
Podcast
Targeting the Dark Matter of the Genome to Treat Diseases
November 12, 2024
Podcast
Targeting the Dark Matter of the Genome to Treat Diseases
May 17, 2023
|
Podcast
RNA-guided programmable therapeutics for fibrosis
May 17, 2023
Podcast
RNA-guided programmable therapeutics for fibrosis
April 14, 2023
|
Podcast
The dark genome as the next revolution in drug discovery
April 14, 2023
Podcast
The dark genome as the next revolution in drug discovery
Year in Review
View HAYA's amazing 2023!